Syngene International Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w7fzdbjichwgwy05596w7kaf.pdf

Key Takeaways


Revenue Performance

Hunt: "We continue to see good demand in the main client markets of US and Europe which - combined with strong execution and forward planning - has helped us deliver solid revenue growth in the third quarter."

Biologics Manufacturing Milestone

Hunt: "With Good Manufacturing Practice (cGMP) certifications from the regulatory agencies in place, the Company is well positioned to fulfil its long-term contract with Zoetis and progress its biologics growth strategy."

Profitability & Margins


Leadership & Capability Build


Inflation & Cost Management

Biswas: "In line with the global trend, we are also facing inflationary pressures, but we have been largely successful in navigating such issues to date and we remain confident about the positive future potential for our business."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growth"High teens" revenue growth (upgraded guidance)FY23
Biologics contract fulfilmentFulfil long-term contract with Zoetis using newly certified facilityUndated (certifications now in place)
Sterile fill-finish operationsGMP-compliant production of injectables for clinical suppliesFrom Q4 FY23 onwards

Key Metrics

MetricQ3 FY23
Revenue from operations₹786 cr, +23% YoY
Reported revenue₹803 cr, +23% YoY
Reported EBITDA₹248 cr, +15% YoY
EBITDA margin (reported)30.9%, vs 33.1% in Q3 FY22
EBITDA margin (from operations)29.4%, vs 31.7% in Q3 FY22
PAT before exceptional item₹110 cr, +5% YoY
PAT margin13.7%, vs 15.9% in Q3 FY22
9M FY23 revenue from operations₹2,199 cr, +19% YoY
9M FY23 PAT before exceptional item₹286 cr, +5% YoY
Full-year revenue growth guidancehigh teens, upgraded, on track
Staff costs₹219 cr, 27.9% of revenue from ops, +12% YoY
Material costs₹206 cr, 26.2% of revenue from ops, +20% YoY
Foreign exchange fluctuationloss of ₹16 cr, vs gain of ₹20 cr in Q3 FY22
Depreciation and amortisation₹95 cr, +21% YoY
Finance costs₹14 cr, +46% YoY
Cash and cash equivalents₹171 cr as of 31 Dec 2022, vs ₹262 cr as of 31 Mar 2022
Net borrowings (current + non-current)₹811 cr as of 31 Dec 2022, vs ₹790 cr as of 31 Mar 2022
Headcount (scientists)more than 5,200